138 related articles for article (PubMed ID: 32726455)
1. Heterogeneous addiction to transforming growth factor-beta signalling in recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma.
Dayal JHS; Mason SM; Salas-Alanis JC; McGrath JA; Taylor RG; Mellerio JE; Blyth K; South AP; Inman GJ
Br J Dermatol; 2021 Apr; 184(4):697-708. PubMed ID: 32726455
[TBL] [Abstract][Full Text] [Related]
2. Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases.
Hwang A; Kwon A; Miller CH; Reimer-Taschenbrecker A; Paller AS
Orphanet J Rare Dis; 2024 May; 19(1):206. PubMed ID: 38769503
[TBL] [Abstract][Full Text] [Related]
3. Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma.
Welponer T; Weber DD; Trattner L; Tockner B; Aminzadeh-Gohari S; Leb-Reichl V; Kaufmann A; Zauner R; Wimmer M; Wally V; Felder TK; Strunk D; Koller U; Bauer JW; Kofler B; Guttmann-Gruber C; Piñon Hofbauer J
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):112-123. PubMed ID: 37669776
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa.
Rami A; Łaczmański Ł; Jacków-Nowicka J; Jacków J
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383666
[TBL] [Abstract][Full Text] [Related]
5. Role of transforming growth factor-β1 in recessive dystrophic epidermolysis bullosa squamous cell carcinoma.
Twaroski K; Chen W; Pickett-Leonard M; Tolar J
Exp Dermatol; 2021 May; 30(5):664-675. PubMed ID: 33595864
[TBL] [Abstract][Full Text] [Related]
6. High levels of type VII collagen expression in recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma keratinocytes increases PI3K and MAPK signalling, cell migration and invasion.
Pourreyron C; Chen M; McGrath JA; Salas-Alanis JC; South AP; Leigh IM
Br J Dermatol; 2014 Jun; 170(6):1256-65. PubMed ID: 24641191
[TBL] [Abstract][Full Text] [Related]
7. Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
Duong T; Wong D; Barrett A; Price H
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637494
[TBL] [Abstract][Full Text] [Related]
8. Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.
Kim M; Murrell DF
Eur J Dermatol; 2015 Apr; 25 Suppl 1():30-2. PubMed ID: 26083672
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
Ng YZ; Pourreyron C; Salas-Alanis JC; Dayal JH; Cepeda-Valdes R; Yan W; Wright S; Chen M; Fine JD; Hogg FJ; McGrath JA; Murrell DF; Leigh IM; Lane EB; South AP
Cancer Res; 2012 Jul; 72(14):3522-34. PubMed ID: 22564523
[TBL] [Abstract][Full Text] [Related]
10. Immune Disregulation in Cutaneous Squamous Cell Carcinoma of Patients with Recessive Dystrophic Epidermolysis Bullosa: A Single Pilot Study.
Filoni A; Cicco G; Cazzato G; Bosco A; Lospalluti L; Tucci M; Cimmino A; Foti C; Marzullo A; Bonamonte D
Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207500
[TBL] [Abstract][Full Text] [Related]
11. Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomas.
Föll MC; Fahrner M; Gretzmeier C; Thoma K; Biniossek ML; Kiritsi D; Meiss F; Schilling O; Nyström A; Kern JS
Matrix Biol; 2018 Mar; 66():1-21. PubMed ID: 29158163
[TBL] [Abstract][Full Text] [Related]
12. Basic fibroblast growth factor: a missing link between collagen VII, increased collagenase, and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
Arbiser JL; Fine JD; Murrell D; Paller A; Connors S; Keough K; Marsh E; Folkman J
Mol Med; 1998 Mar; 4(3):191-5. PubMed ID: 9562977
[TBL] [Abstract][Full Text] [Related]
13. TGFβ-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa.
Knaup J; Gruber C; Krammer B; Ziegler V; Bauer J; Verwanger T
Anal Cell Pathol (Amst); 2011; 34(6):339-53. PubMed ID: 22002724
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20 years' experience of a reference centre in Spain.
Castelo B; Viñal D; Maseda R; Ostios L; Sánchez D; García-Salvatierra B; Escámez MJ; Martínez-Santamaría L; Del Río M; Mora-Rillo M; Vilches Y; Beato MJ; López Gutiérrez JC; Romero N; Santos C; Miranda J; de Lucas R
Clin Transl Oncol; 2019 Nov; 21(11):1573-1577. PubMed ID: 30864020
[TBL] [Abstract][Full Text] [Related]
15. Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa.
Trefzer L; Hess ME; Scholten L; Technau-Hafsi K; Meiss F; Boerries M; Has C; Rafei-Shamsabadi D
Acta Derm Venereol; 2023 Jun; 103():adv4870. PubMed ID: 37338146
[TBL] [Abstract][Full Text] [Related]
16. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
[TBL] [Abstract][Full Text] [Related]
17. Morphological and morphometric analysis of cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a retrospective study.
Filoni A; Cicco G; Lospalluti L; Maglietta A; Foti C; Annichiarico G; Resta L; Bonamonte D
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1707-1714. PubMed ID: 31692111
[TBL] [Abstract][Full Text] [Related]
18. Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts.
Atanasova VS; Russell RJ; Webster TG; Cao Q; Agarwal P; Lim YZ; Krishnan S; Fuentes I; Guttmann-Gruber C; McGrath JA; Salas-Alanis JC; Fertala A; South AP
J Invest Dermatol; 2019 Jul; 139(7):1497-1505.e5. PubMed ID: 30684555
[TBL] [Abstract][Full Text] [Related]
19. Injury-Driven Stiffening of the Dermis Expedites Skin Carcinoma Progression.
Mittapalli VR; Madl J; Löffek S; Kiritsi D; Kern JS; Römer W; Nyström A; Bruckner-Tuderman L
Cancer Res; 2016 Feb; 76(4):940-51. PubMed ID: 26676755
[TBL] [Abstract][Full Text] [Related]
20. Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-β signalling in modifying disease severity.
Odorisio T; Di Salvio M; Orecchia A; Di Zenzo G; Piccinni E; Cianfarani F; Travaglione A; Uva P; Bellei B; Conti A; Zambruno G; Castiglia D
Hum Mol Genet; 2014 Aug; 23(15):3907-22. PubMed ID: 24599399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
